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REVIEWS
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Summary
Sudden death (SD) in childhood is rare, representing only 10% of paediatric mortality after
one year of age. The individual risk is estimated between 1 in 20.000 and 1 in 50.000 per year.
In case of a negative autopsy for cardiac morphologic anomalies, the most presumable cause
remains a genetically-determined malignant primary ventricular arrhythmia. Rhythmic
sudden cardiac death can be categorized as a complication of a cardiomyopathy (dilated or
hypertrophic), or as a primary channelopathy without any structural heart disease. Primary
ventricular arrhythmias include long QT syndrome, Brugada syndrome, short QT syndrome
and Polymorphic Ventricular Tachycardia. The diagnosis of such syndromes relies upon
specific ECG anomalies, personal history of family members, eventually echocardiography
and drug challenge. For some of these diseases, morbid genes have been identified thus
rendering possible the management of pre symptomatic or undiagnosed family members
within specialized multidisciplinary teams. In case of sudden arrhythmic death in children,
the parents and siblings must be examined Rescued sudden death exposes to a high risk of
recurrence. In such patients, the automatic implantable defibrillator has dramatically
improved survival.
© 2008 Published by Elsevier Masson SAS.
Résumé
La mort subite (MS) dans l’enfance est rare, représentant seulement 10 % des morts
pédiatriques après l’âge de 1 an. Le risque individuel est estimé entre 1/20 000 et 1/50 000 par
an. On peut distinguer deux contextes cliniques de MS chez l’enfant : les MS rythmiques sur
cœur sain et les MS compliquant les cardiopathies. Lorsque l’autopsie ne retrouve aucune
anomalie morphologique permettant d’expliquer la mort subite, la cause la plus vraisemblable
reste une arythmie ventriculaire maligne primitive majoritairement d’origine génétique. Parmi
ces arythmies ventriculaires malignes, dues à des anomalies de fonctionnement primitif des
canaux ioniques cardiaques, on distingue le syndrome du QT long, le syndrome de Brugada, le
syndrome du QT court et les tachycardies ventriculaires catécholergiques. Le dépistage
cardiologique de l’un de ces syndromes repose sur l’analyse de l’ECG, les antécédents
personnels de chaque membre de la famille, éventuellement l’échocardiographie ou les tests
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pharmacologiques de sensibilisation. Pour certains de ces syndromes, le ou les gènes en cause
sont connus et rendent possible, au sein d’équipes multidisciplinaires spécialisées, la prise en
charge des apparentés pré-symptomatiques ou symptomatiques dont le diagnostic n’aurait pas
été établi. Toute mort subite rythmique récupérée expose le patient à un risque élevé de
récidive et justifie l’implantation d’un défibrillateur automatique.
© 2008 Published by Elsevier Masson SAS.
Sudden death (SD) in childhood is rare, representing only
10% of paediatric mortality after one year of age. The indi-
vidual risk is estimated between 1 in 20.000 and 1 in 50.000
per year [1]. It is possible to identify two clinically distinct
contexts with underlying heart defects. Congenital heart
diseases are either non repairable (fixed pulmonary hyper-
tension in Eisenmenger’s Syndrome) or repairable (tetra-
logy of Fallot or transposition of the great arteries) [2, 3].
Sudden death following repair of other cardiac defects is
infrequent (only 0.1/1 000 patients/year). Finally, sudden
arrhythmic death can also occur in cardiomyopathy, espe-
cially hypertrophic and, more unusually, dilated or restric-
ted cardiomyopathy [4, 5]. In very rare cases, SD can be due
to a primary electrical disease in a normal heart. In cases of
sudden arrhythmic death in children, the parents and
siblings must be examined. The tests depend on the presu-
med diagnosis of the sudden death. 
Sudden death due to primary malignant
ventricular arrhythmia (MVA)
The majority of sudden deaths in children, that remain
unexplained after autopsy, probably have a primary
arrhythmic origin (table 1). Indeed a certain number of ven-
tricular arrhythmias although lethal can be totally undetec-
table on autopsy. These primary arrhythmias include torsa-
des de pointes degenerating into ventricular fibrillation for
congenital long QT syndrome, catecholaminergic polymor-
phic ventricular tachycardia (CPVT), ventricular fibrillation
complicating Brugada syndrome or short QT syndrome. The
retrospective confirmation of the diagnosis is only possible
when the genetic abnormality is identified in the deceased
subject or detected in one of the family members.
Congenital long QT syndrome
Congenital long QT syndrome (LQTS) is clinically and gene-
tically heterogeneous. It is characterised by a prolongation
of the QT interval, associated with a high risk of life-threa-
tening ventricular arrhythmias (torsades de pointes, ven-
tricular fibrillation) that can lead to syncope and sudden
death [6]. The classic distinction between Jervell and
Lange-Nielsen Syndrome (the recessive form with deafness)
and Romano-Ward Syndrome (the dominant form without
deafness) tends to be forgotten in favour of a classification
based on recent advances in molecular genetics. The genes
responsible for the LQT1, LQT2, LQT5 and LQT6 forms code
for potassium channels (KCNQ1, HERG = KCNH2, KCNE1,
KCNE2 respectively) while the affected gene in the LQT3
form codes for the cardiac sodium channel (SCN5A)
(table 1) [6]. The genetic prevalence is currently estimated
at 1/5 000 [7]. The LQTS phenotype is characterized by a
prolonged QT interval (QTc > 440 ms) measured in leads D2
or V5. Recently, genetic testing has become one of the
reference methods for the diagnosis of LQTS. The genetic
and allelic heterogeneity observed in LQTS and the large
size of some of these genes makes genetic diagnosis diffi-
cult so that it is actually only established in 50-60% of cases
(European populations). Analysis of all the ECG tracings
from members of the same family increases the specificity
and sensitivity for a given patient. Abnormalities in the
length and morphology of ventricular repolarisation are
part of the diagnostic criteria for LQTS. The triggers for the
arrhythmia seem to be dependent on the genotype [8].
Indeed the most frequent trigger of a serious cardiac event
in LQT1 is stress, especially exercise. In LQT2 patients, syn-
cope and ventricular arrhythmias are provoked by sound or
emotion, while for LQT3 patients cardiac events occur at
rest or during sleep [8]. The onset of symptoms is both age
and sex dependent. Boys tend to have earlier clinical onset
than girls until the age of 15, after which women are more
likely to be symptomatic then men [7]. However, it remains
very difficult to evaluate the prognosis of this disease in any
given patient. The incidence of cardiac events is greater in
the LQT1 and LQT2 patients than in LQT3 and the risk
increases with the length of the QTc, independently of the
genotype. Cardiac mortality is comparable between the
three groups but the lethality of cardiac events in group
Tableau 1 Genes responsible for primary ventricular
arrhythmias “Channelopathies”.
Syndromes Genes Effect on current
LQT1 KCNQ1 IKs 
LQT2 KCNH2 IKr 
LQT3 SCN5A INa 
LQT4 Ankyrin-B
LQT5 KCNE1 IKs 
LQT6 KCNH2 IKr 
Jervell syndrome KCNQ1 IKs 
Jervell syndrome KCNE1 IKs 
Timothy syndrome CACNA1C Ca++ 
Short QT KCNH2 IKr 
Short QT KCNQ1 IKs 
Short QT KCNJ2 IK1 
Brugada syndrome SCN5A INa 
CVPT 1 RyR2 Ca++ 
CVPT 2 CASQ2 Ca++ 
Andersen syndrome KCNJ2 IK1 
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LQT3 is higher. So patients with the LQT1 and LQT2 are
more often symptomatic but have fewer lethal events,
while those in the LQT3 group are less likely to be sympto-
matic but with each syncope the risk of death is higher [7].
We have confirmed that in neonatal forms of LQTS with bra-
dycardia due to atrioventricular block (AVB 2:1) the progno-
sis is poor, especially in the first month of life (figure 1) [9].
Conversely, neonatal LQTS with isolated sinus bradycardia
appears to have a better initial outcome. It is possible to
identify two groups, one with conduction problems of the
type AVB 2:1 which seems to be associated preferentially
with mutations in HERG and the other with isolated sinus
bradycardia associated with mutations in KCNQ1 [9].
Treatment options
Beta-blockers are the standard treatment for the preven-
tion of syncope and sudden death and should be prescribed
for all symptomatic patients [6]. Indeed, 20 years ago the
rate of sudden death was considerably high, about 70%
10 years after diagnosis, usually occurring within the second
or third decades of life. From the years 1975-1980, the use of
beta-blockers has lead to a 10 fold decrease in mortality. In
our experience, the decrease in recurrences when treated
with nadolol, at a dosage of 50 mg/m2, is even greater. This
remarkable efficacy of beta-blockers in the prevention of SD
probably varies according to the genotype. Experimental and
clinical data concerning the beneficial effects of beta-bloc-
kers have shown that beta-blockers as monotherapy is most
appropriate for patients with LQT1, and some patients with
LQT2 (often in combination with a permanent pacemaker)
but is probably poorly adapted for some LQT3 patients.
Therefore, any treatment initiated before the genetic dia-
gnosis is made should be revised once the genotype is
known. In all cases of LQTS, whether confirmed or suspec-
ted, preventative measures must be established:.screening and initiation of beta-blocker treatment in all
subjects genetically affected whether symptomatic, or not,
particularly children;.prevention of conditions favouring the occurrence of tor-
sades des pointes (hypokalaemia etc.);.forbid competitive sports and non-competitive sports
according to recommendation [10];.provide children and parents with a list of contra-indicated
drugs known to prolong QT interval [6] (www.qtdrugs.org).
Catecholaminergic polymorphic 
ventricular tachycardia
Catecholaminergic ventricular tachycardia (CVT) is charac-
terised by polymorphic ventricular arrhythmias that are
triggered adrenergically. They occur mainly in children and
adolescents, and are responsible for syncope and SD in the
absence of any other structural heart disease [11, 12]. Car-
diac events occur with emotional and/or physical stress, or
while swimming. In more than a third of cases, syncope is
asociated with seizure, thus explaining delays in diagnosis
because often the initial treatment is an anti epileptic
drug. The baseline resting ECG, shows a normal QTc inter-
val and a mild bradycardia. During stress test, which is the
key examination for diagnosis, there is a threshold for the
appearance of ventricular arrhythmias which is reproduci-
ble and specific for each patient. A characteristic progres-
sion is observed with isolated ventricular premature beats,
first monomorphic then polymorphic, bigeminy, then bidi-
rectional salvoes and finally polymorphic ventricular sal-
voes (figure 2). The genetic basis for CPVT has been eluci-
dated by the finding of autosomal dominant mutations in
the gene coding for the ryanodine type 2 receptor (RyR2)
[12-14]. More recently, two groups have reported closely
related forms of CPVT associated with homozygous muta-
tions in the calsequestrin 2 gene (CASQ2) which codes for a
protein implicated in intra-cellular calcium interactions,
and is also situated in the sarcoplasmic reticulum [15]. The
RyR2 and CASQ2 genes both play a determining role in car-
diac excitation-contraction coupling and in the storage and
release of intra-cytoplasmic calcium.
In the absence of treatment, the mortality rate in CPVT
is very high, reaching 30-50% by the age of 30 years [11, 12]
In addition there is a correlation between the age at which
the first syncope occurs and the severity of the disease, the
earlier the episodes of fainting first occur, the poorer the
prognosis. Beta-blockers have significantly reduced syncope
and SD. The doses of beta-blockers used in the prevention
of syncope are very high, often twice as those used in LQTS
[8]. Nevertheless, it is possible that in adolescents with
CPVT incompletely controlled by a high dose of beta-bloc-
kers the indication for an implantable cardioverter-defi-
brillator (ICD) must be more often considered. Patients
with CPVT due to mutations in RyR2 have a varied clinical
presentation. Among those genetically affected, 20%
show no ventricular arrhythmia during stress test and are
Figure 1. ECG tracing in lead D1 in a newborn.
The sinus rate (P-waves) is at 120/mn and the rate ventricular rate
(QRS) is at 60/mn due to a functional 2 :1 AVB. The QT interval is
very long (QTc = 510 ms). One out of two sinus atrial beats occurs
during the ventricular refractory period.
Figure 2. Stress test ECG in a 12 year old child presenting with
syncope and seizure during effort.
A. The ECG at rest is normal (QTc = 410 ms). B. Appearance of isol-
ted premature ventricular polymorphic beats,first, then couplets
when the heart rate reaches 130/mn. C. During streneous exercise,
rapid polymorphic salvoes occur with near-syncope.
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completely asymptomatic. There is a predominance of
females (80%) in this healthy carrier group [12]. This obser-
vation is in agreement with recent data which show that
male gender is a risk factor for cardiac events in patients
with RyR2 mutations [12]. Nevertheless, considering that
the first symptom may be sudden death, it is recommended
to treat all genetically identified subjects and those
patients that are asymptomatic but have ventricular
arrhythmia during exercise. Sports is contra-indicated,
including for patients treated with beta-blockers.
Brugada syndrome
Brugada syndrome is characterized by a delayed conduction
in the right ventricle and an elevated ST segment in the
right precordial leads on the resting ECG (figure 3), associa-
ted with a high risk of ventricular fibrillation and SD [15-
17]. The prevalence of the syndrome is between 4 and 12%
of all causes sudden death. The syndrome is responsible for
half the sudden deaths occurring in adult patients with
apparently normal hearts. The only treatment having any
proven effect on the prevention of SD is the implantable
cardioverter-defibrillator (ICD). The ECG signs are someti-
mes intermittent and can be unmasked during a drug chal-
lenge with a sodium channel blocker (ajmaline or flecainide
in children). Subjects are considered to meet phenotypic
criteria if demonstrating typical electrocardiogram anoma-
lies (type 1), either spontaneously on the surface ECG, or
during a drug challenge. In case of a symptomatic patient
(syncope, aborted sudden death) with typical ECG type 1
Brugada, an ICD is recommaned. Ventricular stimulation
may be discussed but it’s diagnostic and prognostic value
remains a matter of debate. The symptoms, which in half
the cases are syncope leading to death without prodrome,
occur primarily in men of 40 years of age. Warning signs are
extremely rare in children and occur most often with fever
[17]. Probst and co-workers reported the 37-month follow-
up of 30 children with Brugada syndrome. In symptomatic
children, arrhythmic events occurred mainly with fever
with a spontaneous type 1 Brugada ECG. Among the 5 chil-
dren who received an ICD, 2 had an appropriate shock
during follow-up. However, complications are very fre-
quent in implanted children and the indication for ICD in
small children remains the exception. Treatment with
hydroquinidine could allow to postpone the time to implan-
tation [17]. Asymptomatic children, diagnosed during family
screening seem to have a good prognosis [17].
In the context of family screening or systematic disco-
very, a drug challenge or ventricular stimulation may be pro-
posed for asymptomatic patients over 16 years of age [17].
The genetic origin can be confirmed in approximately 20%
of cases, by the identification of mutations in the SCN5A
gene, which codes for the cardiac sodium channel. 
Short QT syndrome
Short QT syndrome (SQTS), is a newly described entity [18,
19] characterized by a short QT interval (QTc ≤ 300ms) and
a high risk of syncope and SD due to malignant ventricular
arrhythmias. The phenotype of three families has been
recently published. The syndrome is hereditary, since in the
affected families, the phenotype is found in several
patients from different generations. The syncope and SD
may occur at rest but also during effort. The electrocardio-
graphic anomaly (QTc) is sometimes associated with early
onset of atrial fibrillation. Mutations in the genes HERG
(=KCNH2), KCNQ1 and KCNJ2 have been identified in
patients with SQTS [19]. Expression studies of these muta-
tions show a shortening of the action potential. Electrophy-
siological studies show decreased atrial and ventricular
refractory periods and ventricular vulnerability to arrhyth-
mia in the majority of patients. ICD implantation is the only
treatment available which has proven efficacy in sudden
death prevention. 
Support for families in the event 
of sudden death in one of the children
Cardiological screening for one of these syndromes is based
on the analysis of the ECG, medical history of each family
member, and eventually echocardiography or drug chal-
lenge. For most of these syndromes, the morbide gene (or
genes) are known and allow, in conjunction with clinical
examination, the screening of family relatives, both symp-
tomatic and asymptomatic,This type of screening can not
be considered as a routine examination. The indications
must be carefully examined and the families should be
referred to multidisciplinary teams, which include a cardio-
logist, a geneticist and a psychologist. The patient must be
fully informed of the implications of the test Time for deci-
sion must be respected. Results must be given as part of a
programme which includes long-term follow-up.
Presymptomatic diagnosis
Presymptomatic testing of the relatives of an affected
patient can enable the identification of those who are at
risk of cardiac events and could benefit from close cardio-
logical monitoring. However, given the absence of a cura-
tive treatement, and sometimes preventive treatment, the
test must be carried out only after the patient has been
fully informed during a multi-disciplinary consultation.
Indeed, ICD is the only therapeutic option that has proven
benefit in the secondary prevention of SD.
Prenatal counselling
When there is a known familial mutation, the diagnosis is tech-
nically possible from the 10th week of pregnancy, although
Figure 3. 12 lead ECG recorded in a 12 year-old child after a syn-
cope, showing a type 1 Brugada ECG pattern in leads V1 and V2.
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not without risk for the foetus. The test should perhaps there-
fore only be considered if the decision for abortion depends on
the outcome. For an affected parent the risk of transmitting
these autosomal dominant syndromes is 50% and it is impossi-
ble to predict the penetrance of the disease Therefore,prena-
tal diagnosis is not performed for LQTS and catecholaminergic
polymorphic ventricular tachycardia because preventive
medical treatment exists for these syndromes. 
The diagnostic test
Molecular biology allows to confirm the gene involved and
the type of mutation. When the mutation has been identi-
fied in the proband, it can be easily identified in presymp-
tomatic relatives. 
Prognostic evaluations
The identification of patients at high risk of arrhythmic com-
plications can lead to prophylactic measures. For LQTS, the
genotype is one of the parameters for risk stratification. 
Conclusion
The majority of children who experience SD have known
heart diseases, particularly repaired congenital heart
defects. Sometimes no morphological abnormality are found
at clinical examination or autopsy to explain the SD. In these
children, the most likely cause remains a primary malignant
ventricular arrhythmia due to a morbide gene. In case of a
negative autopsy, it is recommaned to biopsy cardiac tissue.
Subsequent DNA analysis can provide data supporting a here-
ditary arrhythmic syndrome. Family members should be sent
to centres used to deal with such conditions who work in
multidisciplinary teams with the support of a cardiologist, a
geneticist, a psychologist and a molecular biologist.
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